Meeting
2021 ASCO Annual Meeting
Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).
Authors
Dae Young Zang
Hallym University Sacred Heart Hospital, Anyang, Korea South
Dae Young Zang , Hye Sook Han , Bum Jun Kim , Hee-Jung Jee , Young Ju Suh , Hyonggin An , Ji-Hye Byun , Dong Sook Kim , Se Hoon Park , Sun Young Rha , Do-Youn Oh , Jong Gwang Kim , Woo Kyun Bae , In-Ho Kim , Sun Jin Sym , So Yeon Oh , Hyeong Su Kim , Keun Wook Lee , Min-Hee Ryu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT04192734
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4056)
DOI
10.1200/JCO.2021.39.15_suppl.4056
Abstract #
4056
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Exploring real-world outcomes with nivolumab plus chemotherapy in patients with advanced gastroesophageal adenocarcinoma.
First Author: Clara Chen
Poster
2020 ASCO Virtual Scientific Program
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO.
First Author: Sylvie Lorenzen
Poster
2020 Gastrointestinal Cancers Symposium
Real-world outcomes of first-line U.S. patients with unresectable advanced or metastatic gastroesophageal adenocarcinoma by primary tumor location.
First Author: Veena Shankaran
First Author: Sylvie Lorenzen